About Repros
Company Overview
Board of Directors and Management
Pipeline
Androxal
®
Male Fertility Maintenance/Improvement
Type II Diabetes
Publications
Proellex
®
Uterine Fibroids
Endometriosis
Publications
Clinical Trials
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
May 15, 2012
Repros Therapeutics Inc.® Reports First Quarter 2012 Financial Results
May 9, 2012
FDA and Repros Reach Agreement for Androxal® Registration Program
April 30, 2012
Repros' Proellex®-V Clears Important Hurdle in Uterine Fibroid Program
March 27, 2012
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2011 Financial Results
There are no scheduled events.
"I've been on male birth control and didn't know it"
says one patient dealing with male infertility.
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
